CXCR3 and ovarian carcinoma: OrfV has also been used in a murine end-stage ovarian cancer model showing efficacy as a monotherapy through stimulation of NK cell responses leading to enhanced recruitment of CD8+ CXCR3-expressing T cells through upregulation of CXCR3 ligands (156).